According to Zen Score, the 3 best drug store stocks to buy right now are:
1. Leafly Holdings (NASDAQ:LFLY)
Leafly Holdings (NASDAQ:LFLY) is the top pharmaceutical retailer stock with a Zen Score of 50, which is 23 points higher than the pharmaceutical retailer industry average of 27. It passed 16 out of 33 due diligence checks and has strong fundamentals. Leafly Holdings has seen its stock lose -91.61% over the past year, underperforming other pharmaceutical retailer stocks by -44 percentage points.
Leafly Holdings has an average 1 year
price target of $4.00, an upside of 566.67% from Leafly Holdings's current stock price of $0.60.
Leafly Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Leafly Holdings, 0% have issued a Strong Buy rating, 50% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Petmed Express (NASDAQ:PETS)
Petmed Express (NASDAQ:PETS) is the second best pharmaceutical retailer stock with a Zen Score of 42, which is 15 points higher than the pharmaceutical retailer industry average of 27. It passed 14 out of 38 due diligence checks and has strong fundamentals. Petmed Express has seen its stock lose -16% over the past year, overperforming other pharmaceutical retailer stocks by 31 percentage points.
Petmed Express has an average 1 year
price target of $18.00, a downside of -16.36% from Petmed Express's current stock price of $21.52.
Petmed Express stock has a consensus Strong Sell recommendation according to Wall Street analysts. Of the 1 analyst covering Petmed Express, 0% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 100% have issued a Strong Sell.
3. Greenlane Holdings (NASDAQ:GNLN)
Greenlane Holdings (NASDAQ:GNLN) is the third best pharmaceutical retailer stock with a Zen Score of 38, which is 11 points higher than the pharmaceutical retailer industry average of 27. It passed 12 out of 33 due diligence checks and has average fundamentals. Greenlane Holdings has seen its stock lose -96.69% over the past year, underperforming other pharmaceutical retailer stocks by -49 percentage points.
Greenlane Holdings has an average 1 year
price target of $1.38, an upside of 216.09% from Greenlane Holdings's current stock price of $0.44.
Greenlane Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Greenlane Holdings, 0% have issued a Strong Buy rating, 50% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.